Geovax Labs, Inc. together with Vivalis SA announced the signing of a letter of intent (LOI) for joint collaboration and commercial license on the use of Vivalis´ EBx(R) technology, to manufacture the MVA component of the GeoVax HIV-1 vaccine. This agreement between GeoVax and Vivalis creates a worldwide strategic partnership between Vivalis and GeoVax, designed to combine Vivalis´ cutting-edge vaccine manufacturing technology with GeoVax´s promising HIV vaccine. The breakthrough manufacturing technology developed by Vivalis, and now to be further developed through collaboration with GeoVax, will create a new standard for manufacture of the MVA component of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited production capabilities, less competitive. Vivalis´ EBx(R) manufacturing platform, with its increased effectiveness, superior quality and reliability, will speed time to market MVA vaccine product availability in ample quantities to meet sizeable demand and expectedly at a lesser cost.

GeoVax Labs Inc. provided an operational update on the company´s progress towards entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic human trials with its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS vaccines have previously been reported. Planned Phase 2 Human Clinical Trial for Prevention of AIDS. The Company´s Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to start early this fall, subject to FDA approval.

Geovax Labs, Inc., Annual General Meeting, Jun 17, 2008, at 10:00 US Eastern Time. Location: The J. Fonda Conference Center, 1256 Briarcliff Road, Atlanta, Georgia,United States. Agenda: To elect six directors to serve until the 2009 Annual Meeting of Stockholders; to reincorporate in Delaware; to ratify the appointment of Porter Keadle Moore LLP as the independent registered public accounting firm of GeoVax Labs, Inc. for the fiscal year ending December 31, 2008 and to consider such other business as properly may come before the Annual Meeting or any adjournments thereof .